Sawtooth Solutions LLC raised its position in shares of AstraZeneca plc (NYSE:AZN) by 235.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,614 shares of the company’s stock after purchasing an additional 17,969 shares during the period. Sawtooth Solutions LLC’s holdings in AstraZeneca were worth $888,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also recently bought and sold shares of AZN. Pinnacle Wealth Planning Services Inc. purchased a new stake in shares of AstraZeneca during the 4th quarter worth about $101,000. Valeo Financial Advisors LLC purchased a new stake in shares of AstraZeneca during the 3rd quarter worth about $133,000. Delpha Capital Management LLC purchased a new stake in shares of AstraZeneca during the 4th quarter worth about $152,000. Calton & Associates Inc. purchased a new stake in shares of AstraZeneca during the 4th quarter worth about $181,000. Finally, Wealthcare Advisory Partners LLC purchased a new stake in shares of AstraZeneca during the 3rd quarter worth about $184,000. 15.13% of the stock is owned by institutional investors.
A number of research analysts recently weighed in on the company. Zacks Investment Research downgraded AstraZeneca from a “hold” rating to a “sell” rating in a research note on Wednesday, January 3rd. ValuEngine raised AstraZeneca from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 3rd. Leerink Swann raised their price objective on AstraZeneca from $36.00 to $38.00 and gave the company a “market perform” rating in a research note on Tuesday, February 6th. BMO Capital Markets set a $40.00 price objective on AstraZeneca and gave the company a “buy” rating in a research note on Tuesday, February 20th. Finally, JPMorgan Chase & Co. raised AstraZeneca from a “neutral” rating to an “overweight” rating in a research note on Friday, December 29th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. AstraZeneca has an average rating of “Hold” and a consensus price target of $36.32.
Shares of AstraZeneca plc (NYSE AZN) opened at $34.38 on Friday. The stock has a market capitalization of $87,663.53, a P/E ratio of 14.54, a price-to-earnings-growth ratio of 1.80 and a beta of 0.71. The company has a quick ratio of 0.62, a current ratio of 0.80 and a debt-to-equity ratio of 0.93. AstraZeneca plc has a fifty-two week low of $28.43 and a fifty-two week high of $36.70.
AstraZeneca (NYSE:AZN) last released its earnings results on Friday, February 2nd. The company reported $1.30 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.44 by $0.86. The firm had revenue of $5.78 billion for the quarter, compared to analyst estimates of $5.49 billion. AstraZeneca had a return on equity of 34.74% and a net margin of 13.36%. The company’s revenue was up 3.4% on a year-over-year basis. During the same quarter last year, the firm posted $1.21 EPS. equities research analysts forecast that AstraZeneca plc will post 1.7 earnings per share for the current fiscal year.
The firm also recently announced a semiannual dividend, which was paid on Monday, March 19th. Shareholders of record on Friday, February 16th were issued a $0.95 dividend. This represents a yield of 5.62%. The ex-dividend date was Thursday, February 15th. AstraZeneca’s dividend payout ratio (DPR) is currently 57.81%.
ILLEGAL ACTIVITY WARNING: This piece of content was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://ledgergazette.com/2018/03/23/sawtooth-solutions-llc-purchases-17969-shares-of-astrazeneca-plc-azn.html.
AstraZeneca Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.